Insider Selling: Diaceutics (LON:DXRX) Insider Sells £475,000 in Stock

Diaceutics PLC (LON:DXRX) insider Jordan Clark sold 250,000 shares of the company’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of GBX 190, for a total value of £475,000.

Diaceutics Trading Down 0.5%

LON DXRX traded down GBX 1 during trading hours on Friday, hitting GBX 194. The company’s stock had a trading volume of 330,586 shares, compared to its average volume of 298,740. The stock has a fifty day moving average of GBX 188.20 and a 200 day moving average of GBX 160.85. The company has a quick ratio of 9.92, a current ratio of 2.55 and a debt-to-equity ratio of 5.40. Diaceutics PLC has a twelve month low of GBX 125 and a twelve month high of GBX 210. The firm has a market capitalization of £164.85 million, a P/E ratio of -606.25 and a beta of 0.88.

Diaceutics (LON:DXRX) last announced its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) EPS for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. Equities research analysts forecast that Diaceutics PLC will post 1.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group restated a “buy” rating and issued a GBX 215 price objective on shares of Diaceutics in a research report on Tuesday. Two analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of GBX 215.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.